The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)
Zeidan A, Forde P, Symons H, Chen A, Smith B, Fuchs E, Luznik L, Jones R, Bolaños-Meade J. The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). Blood 2013, 122: 4629. DOI: 10.1182/blood.v122.21.4629.4629.Peer-Reviewed Original ResearchDonor lymphocyte infusionPosttransplantation cyclophosphamideComplete responseGVHD prophylaxisMRD relapseLymphocyte infusionHematologic relapseCR rateDoses of DLIHLA-haploidentical bone marrow transplantationReasonable starting doseBone marrow transplantationDisease-specific criteriaOff-label useDuration of survivalAML ptsChronic GVHDAllogeneic BMTSevere graftStarting doseUnacceptable toxicityDonor chimerismMedian ageDisease relapseMarrow transplantation